Lincoln Pharmaceuticals (531633) Q4 24/25 earnings summary

Executive summary

• Reported FY25 standalone net profit of Rs. 82.44 crore, EBITDA of Rs. 123.97 crore, and total income of Rs. 645.71 crore, with a recommended dividend of 18% (Rs. 1.80 per share).

• Q4 FY25 standalone net profit was Rs. 11.62 crore, EBITDA Rs. 19.84 crore, and total income Rs. 161.30 crore.

• FII holding increased to 5.0% as of March 2025 from 3.93% in March 2024.

• Company targets Rs. 750 crore revenue in FY26, focusing on high-value products and new markets.

Financial highlights

• FY25 total income grew 5% year-over-year to Rs. 645.71 crore; EBITDA declined 7.7% to Rs. 123.97 crore.

• Net profit for FY25 fell 11.7% year-over-year to Rs. 82.44 crore; EPS at Rs. 41.11, down from Rs. 46.58.

• Q4 FY25 EPS was Rs. 5.78; Q4 net profit Rs. 11.62 crore.

• Profit before tax for FY25 was Rs. 109.19 crore, down from Rs. 122.24 crore in FY24.

• Cash and cash equivalents at year-end stood at Rs. 1,297.44 lakh (standalone) and Rs. 1,341.38 lakh (consolidated).

Outlook and guidance

• Revenue target of Rs. 750 crore for FY26, driven by business expansion, new product launches, and entry into new markets.

• Focus on operational excellence, R&D, and global expansion, including recent entry into Canada and product registrations in new geographies.